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Recombinant clotting factor VIII
concentrates: Heterogeneity and high-purity
evaluation
Factor VIII is an important glycoprotein involved in hemostasis. Insertion of expression
vectors containing either the full-length cDNA sequence of human factor VIII (FLrFVIII)
or B-domain deleted (BDDrFVIII) into mammalian cell lines results in the production of
recombinant factor VIII (rFVIII) for therapeutic usage. Three commercially available
rFVIII concentrates (Advates, Helixate NexGens and Refactos), either FLrFVIII or
BDDrFVIII, were investigated by 1- and 2-DE and MS. The objective of this study was to
compare the heterogeneity and the high purity of both rFVIII preparations before and
after thrombin digestion. In particular, the 2-D gel was optimized to better highlight the
presence of contaminants and many unexpected proteins. Recombinant strategies
consisting of insertion of expression vectors containing BDDrFVIII and FLrFVIII
resulted in homogeneous and heterogeneous protein products, respectively, the latter
consisting in a heterogeneous mixture of various B-domain-truncated forms of the
molecule. Thrombin digestion of all the three rFVIII gave similar final products, plus
one unexpected fragment of A2 domain missing 11 amino acids. Regarding the
contaminants, Helixate NexGens showed the presence of impurities, such as
Hsp70 kDa, haptoglobin and proapolipoprotein; Refactos showed glutathione S-trans-
ferase and b-lactamase, whereas Advates apparently did not contain any contaminants.
The proteomic approach will contribute to improving the quality assurance and manu-
facturing processes of rFVIII concentrates. In this view, the 2-DE is mandatory for
revealing the presence of contaminants.
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1 Introduction
Hemophilia A (factor VIII deficiency) is an X-linked,
recessive, bleeding disorder caused by heterogeneous
mutations in the FVIII gene, which affects one in 10 000
individuals (one in 5000 males) in most populations.
Human clotting factor VIII (FVIII) is a non-enzymatic
plasma glycoprotein that plays an essential role in the
intrinsic pathway of the blood coagulation cascade [1]. The
degree of FVIII deficiency correlates with the frequency of
clinically significant bleeding [2]. Two categories of FVIII
concentrates are commercially available, namely plasma-
derived or recombinant FVIII: the former is extracted from
human blood, while the latter is biosynthesized through
recombinant DNA technology. Infusion of both plasma-
derived and/or recombinant factor VIII (rFVIII) is the
standard strategy for treating hemorrhage in patients with
hemophilia A.
Native protein is synthesized as a single polypeptide
chain of 2332 amino acids, which is preceded by a 19-resi-
due hydrophobic signal peptide of importance for the
secretion. The protein contains six main domains: three A-
type domains, a central B domain and two C-type domains.
In detail, domains can be distinguished as follows: three
small acidic peptide regions (30–40 designed by ‘‘a’’) join
(i) the A1 and A2 domains (residues 337–372); (ii) the A2
and B domains (residues 711–740); and (iii) the last one
connects the B domain with the amino terminal of the
A3 domain (residues 1649–1689). Therefore, the domain
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